Justin Wilson
Family · Cullman, ALNPI 1417420704
Payments from drug & device makers
Across 323 payments — averaging $3373.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sekisui Diagnostics LLC$751K
- Orasure Technologies Inc.$181K
- Visby Medical, Inc.$105K
- BD$44K
- Modernatx, Inc.$3K
- AstraZeneca$639
- plus $4K from 32 others
What the payments were for
- Travel & lodging$2,33029%
- Food & beverage$5,68571%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sekisui Diagnostics LLC | 5 | $751,295 |
| Orasure Technologies Inc. | 14 | $181,370 |
| Visby Medical, Inc. | 2 | $105,156 |
| BD | 1 | $43,720 |
| Modernatx, Inc. | 18 | $3,007 |
| AstraZeneca | 35 | $639 |
| GSK | 39 | $615 |
| Pfizer | 32 | $606 |
| Novo Nordisk | 17 | $365 |
| Astellas Pharma US Inc | 21 | $359 |
| Lilly USA, LLC | 12 | $216 |
| Amgen(2 entities) | 11 | $213 |
| Bayer | 14 | $206 |
| AbbVie | 11 | $203 |
| E.r. Squibb & Sons, L.L.C. | 11 | $178 |
| Exact Sciences | 9 | $167 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $145 |
| Dexcom, Inc. | 8 | $144 |
| Boehringer Ingelheim | 9 | $142 |
| Merck | 6 | $139 |
| Novartis | 6 | $118 |
| Shield Therapeutics Inc | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 4 | $41 |
| Eisai Inc. | 2 | $40 |
| Lundbeck LLC | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Mylan Specialty L.p. | 2 | $33 |
| Johnson & Johnson | 2 | $31 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Philips North America LLC | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Boston Scientific | 1 | $24 |
| Biogen | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $2 |
How this compares
$1,089,557 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 168 | $202,217 |
| FarxigaDapagliflozin Propanediol | 215 | $193,785 |
| EliquisApixaban | 103 | $90,596 |
| JardianceEmpagliflozin | 78 | $70,464 |
| MounjaroTirzepatide | 45 | $55,296 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $49,922 |
| JanuviaSitagliptin Phosphate | 26 | $36,317 |
| XareltoRivaroxaban | 20 | $17,261 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $16,966 |
| TradjentaLinagliptin | 25 | $15,054 |
| Spiriva HandihalerTiotropium Bromide | 23 | $14,837 |
| MyrbetriqMirabegron | 26 | $14,039 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $12,884 |
| TrulicityDulaglutide | 12 | $11,223 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 15 | $9,454 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $639 | $209,784250 claims |
| Novo NordiskOzempic | $365 | $202,217168 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat | $142 | $92,414115 claims |
| PfizerEliquis | $606 | $90,596103 claims |
| Lilly USA, LLCMounjaro, Trulicity | $216 | $66,51957 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $615 | $55,04673 claims |
| MerckJanuvia | $139 | $36,31726 claims |
| Johnson & JohnsonXarelto | $31 | $17,26120 claims |
| Astellas Pharma US IncMyrbetriq | $359 | $14,03926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Cullman
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.